All In Biotech

NDA 020702 · Upjohn

Lipitor

Atorvastatin Calcium · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 17, 1996

Approved uses

11

Original approval plus efficacy supplements

Registered trials

1,099

271 Phase 3, 75 recruiting

FAERS reports

248,656

160,978 serious, 18,815 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2024.

LIPITOR is indicated: • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. • As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and...

Mechanism: LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • LIPITOR · ATORVASTATIN CALCIUM EQ 80MG BASE · TABLET, ORAL · Prescription · TE AB
  • LIPITOR · ATORVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • LIPITOR · ATORVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • LIPITOR · ATORVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Atorvastatin" as an intervention, any sponsor and status, largest first.

All 1,099 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue14,464
  • drug ineffective13,345
  • nausea12,922
  • diarrhoea11,692
  • dyspnoea11,668
  • type 2 diabetes mellitus11,263
  • pain10,427
  • headache10,307
  • dizziness10,189
  • myalgia10,017
  • asthenia9,153
  • arthralgia8,830

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,709
20057,580
20068,146
20076,977
20086,528
20097,351
201014,619
201111,544
201213,815
201310,592
201415,345
201515,342
201614,718
201712,745
201812,859
201913,144
202012,183
202110,534
202210,498
20239,454
20249,967
202510,971
20268,029

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lipitor (Atorvastatin Calcium)

2024 spending

$26.8M

Beneficiaries

6,920

23,269 claims

Per beneficiary

$3,873

$15.71 per unit

View as table
YearSpending
2020$73,147,637
2021$39,227,775
2022$34,489,246
2023$32,942,705
2024$26,798,187

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,633 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.